Protective Effects of Silymarin on Gentamicin-Induced Nephrotoxicity in Infectious Patients: A Randomized Double Blinded Placebo-Controlled Clinical Trial

Motahareh Mahi-birjand ^1,2 , Iman Karimzadeh ³, Asghar Zarban ⁴, Meghdad Abdollahpour-Alitappeh ⁵ , Seyed Alireza Saadatjoo ⁶, Masood Ziaee ¹ *

Cited by CrossRef: 3

1- Ghiasian M, Nafisi H, Ranjbar A, Mohammadi Y, Ataei S. Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing–remitting multiple sclerosis: A clinical trial study. J Biochem & Molecular Tox. 2021;35(8) [Crossref]

2- Aryan H, Farahani R, Chamanara M, Elyasi S, Jaafari M, Haddad M, Sani A, Ardalan M, Mosaed R. Evaluation of the efficacy of oral nano‐silymarin formulation in hospitalized patients with COVID‐19: A double‐blind placebo‐controlled clinical trial. Phytotherapy Research. 2022;36(10):3924 [Crossref]

3- Bahari H, Shahraki Jazinaki M, Rashidmayvan M, Taheri S, Amini M, Malekahmadi M. The effects of silymarin consumption on inflammation and oxidative stress in adults: a systematic review and meta-analysis. Inflammopharmacol. 2024;32(2):949 [Crossref]

Submit Your Paper Editorial Board Instructions for Authors Instructions for Reviewers Contact Us Editorial Policies Peer Review Archive

Indexing & Abstracting:

Follow us on LinkedIn
Follow us on Twitter

Director-in-Charge:
Prof. Khosro Adibkia

Editor-in-Chief:
Prof. Ali Shayanfar

Follower of ICMJE